SET Antibodies

Target Information

Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher. Belongs to the nucleosome assembly protein (NAP) family. Widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor. 2 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

2PP2A; chromatin remodelling factor; HLA-DR-associated protein II; I-2PP2A; I2PP2A; IGAAD; Inhibitor of granzyme A-activated DNase; inhibitor-2 of protein phosphatase-2A; IPP2A2; MRD58; PHAPII; Phosphatase 2A inhibitor I2PP2A; protein phosphatase type 2A inhibitor; Protein SET; SET; SET nuclear oncogene; SET nuclear proto-oncogene; SET translocation (myeloid leukemia-associated); TAF-I; TAF-IBETA; Template-activating factor I; Template-Activating Factor-I, chromatin remodelling factor